Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study.
Freyer G, Martinez-Jañez N, Kukielka-Budny B, Ulanska M, Bourgeois H, Muñoz M, Morales S, Calero JB, Cortesi L, Pintér T, Palácová M, Cherciu N, Petru E, Ettl J, de Almeida C, Villanova G, Raymond R, Minh CTT, Rodrigues A, Cazzaniga ME. Freyer G, et al. Among authors: palacova m. Breast. 2024 Apr;74:103681. doi: 10.1016/j.breast.2024.103681. Epub 2024 Feb 9. Breast. 2024. PMID: 38377732 Free PMC article. Clinical Trial.
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M; NeoALTTO Study Team. Baselga J, et al. Among authors: palacova m. Lancet. 2012 Feb 18;379(9816):633-40. doi: 10.1016/S0140-6736(11)61847-3. Epub 2012 Jan 17. Lancet. 2012. PMID: 22257673 Free PMC article. Clinical Trial.
The guidelines for clinical practice for carriers of germline mutations in the Lynch syndrome predisposition genes MLH1, MSH2, MSH6, PMS2 and large deletions of EPCAM (4.2024).
Novotný J, Cibula D, Curtisová V, Dubová O, Foretová L, Germanová A, Janatová M, Havránek O, Hojsáková M, Hudcová M, Koudová M, Krutílková V, Palacova M, Paulich S, Petrakova K, Presl J, Puchmajerová A, Soukupová J, Šenkeříková M, Šimková Z, Štěpánková H, Šubrt I, Tachecí I, Tesner P, Urban O, Veselá K, Vilímová Š, Vlčková Z, Vočka M, Weinberger V, Zikán M, Zimovjanová M, Kleibl Z, Kleiblová P. Novotný J, et al. Among authors: palacova m. Klin Onkol. 2024;38(5):384-389. doi: 10.48095/ccko2024384. Klin Onkol. 2024. PMID: 39516038 English.
The guidelines for clinical practice for carriers of germline mutations in hereditary breast, ovarian, prostate, and pancreatic cancer predisposition genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 (4.2024).
Kleiblová P, Novotný J, Cibula D, Curtisová V, Dubová O, Foretová L, Germanová A, Janatová M, Havránek O, Hojsáková M, Hudcová M, Koudová M, Krutílková V, Palacova M, Paulich S, Petrakova K, Presl J, Puchmajerová A, Soukupová J, Šenkeříková M, Šimková Z, Štěpánková H, Šubrt I, Tachecí I, Tesner P, Urban O, Veselá K, Vilímová Š, Vlčková Z, Vočka M, Weinberger V, Zikán M, Zimovjanová M, Kleibl Z. Kleiblová P, et al. Among authors: palacova m. Klin Onkol. 2024;38(4):292-299. doi: 10.48095/ccko2024292. Klin Onkol. 2024. PMID: 39174333 English.
Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial.
Borstnar S, Palacova M, Łacko A, Timcheva C, Gal-Yam EN, Papazisis K, Beniak J, Kudela P, Rubovszky G. Borstnar S, et al. Among authors: palacova m. Radiol Oncol. 2022 May 17;56(2):238-247. doi: 10.2478/raon-2022-0020. Radiol Oncol. 2022. PMID: 35575587 Free PMC article. Clinical Trial.
Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial.
Campone M, De Laurentiis M, Zamagni C, Kudryavcev I, Agterof M, Brown-Glaberman U, Palácová M, Chatterjee S, Menon-Singh L, Wu J, Martín M. Campone M, et al. Among authors: palacova m. Breast Cancer Res Treat. 2022 May;193(1):95-103. doi: 10.1007/s10549-022-06543-1. Epub 2022 Feb 25. Breast Cancer Res Treat. 2022. PMID: 35212906 Clinical Trial.
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Diéras V, Han HS, Kaufman B, Wildiers H, Friedlander M, Ayoub JP, Puhalla SL, Bondarenko I, Campone M, Jakobsen EH, Jalving M, Oprean C, Palácová M, Park YH, Shparyk Y, Yañez E, Khandelwal N, Kundu MG, Dudley M, Ratajczak CK, Maag D, Arun BK. Diéras V, et al. Among authors: palacova m. Lancet Oncol. 2020 Oct;21(10):1269-1282. doi: 10.1016/S1470-2045(20)30447-2. Epub 2020 Aug 27. Lancet Oncol. 2020. PMID: 32861273 Clinical Trial.
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial.
Saura C, Oliveira M, Feng YH, Dai MS, Chen SW, Hurvitz SA, Kim SB, Moy B, Delaloge S, Gradishar W, Masuda N, Palacova M, Trudeau ME, Mattson J, Yap YS, Hou MF, De Laurentiis M, Yeh YM, Chang HT, Yau T, Wildiers H, Haley B, Fagnani D, Lu YS, Crown J, Lin J, Takahashi M, Takano T, Yamaguchi M, Fujii T, Yao B, Bebchuk J, Keyvanjah K, Bryce R, Brufsky A; NALA Investigators. Saura C, et al. Among authors: palacova m. J Clin Oncol. 2020 Sep 20;38(27):3138-3149. doi: 10.1200/JCO.20.00147. Epub 2020 Jul 17. J Clin Oncol. 2020. PMID: 32678716 Free PMC article. Clinical Trial.
Effectiveness of Neoadjuvant Therapy with Platinum-Based Agents for Patients with BRCA1 and BRCA2 Germline Mutations - A Retrospective Analysis of Breast Cancer Patients Treated at MMCI Brno.
Holánek M, Bílek O, Nenutil R, Kazda T, Selingerová I, Zvaríková M, Palácová M, Krásenská M, Vyzula R, Petráková K. Holánek M, et al. Among authors: palacova m. Klin Onkol. 2019 Summer;32(Supplementum2):31-35. doi: 10.14735/amko2019S31. Klin Onkol. 2019. PMID: 31409079 English.
35 results